Strides Pharma Science net profit rises 82 percent at Rs 131.5 crore in Q2

Published On 2025-11-01 09:33 GMT | Update On 2025-11-01 09:33 GMT

New Delhi: Strides Pharma Science Ltd has posted a sharp 82 percent rise in consolidated net profit at Rs 131.52 crore for the quarter ended September 30, 2025, on the back of robust revenue growth in other regulated markets and lower expenses. The Bengaluru-based drugmaker had reported a consolidated net profit of Rs 72.3 crore in the same quarter last year.

Consolidated revenue from operations increased to Rs 1,220.83 crore from Rs 1,166.93 crore a year earlier, while total expenses edged down to Rs 1,085.03 crore from Rs 1,104.61 crore.

Commenting on the performance, Strides Pharma Science MD & Group CEO, Badree Komandur said, "Strides continues to deliver a strong performance in Q2FY26, with growth primarily driven by the 'other regulated markets'." In an investor presentation, the company said in Q2 FY26 'other regulated markets' revenue was at USD 44 million, at a growth of 16 per cent. All regulated markets excluding the US form part of the Other Regulated Markets.

In the US market Q2FY26 revenue was at USD 73 million, up 2 per cent YoY despite intense competition in recent launches from new entrants, PTI reported.

Growth markets, including Africa operations and new geographies of LATAM (Latin America), MENA (Middle East and North Africa) and APAC (Asia-Pacific) registered revenue of USD 17 million, up 7 per cent, it added.

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor- funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries.

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Strides Pharma Science net profit rises 82 percent at Rs 131.5 crore in Q2

Similar News

Boehringer Ingelheim Told to File Separate Phase IV Trial Plan for Empagliflozin

Pune Pharmacist Under Probe for Supplying Expired Actrapid Insulin, Wrong Tablets to Patient

MSN Labs Gets SEC Go-Ahead to Conduct Phase IV Clinical Trial on Elagolix for Endometriosis

Ex-CBIC Officer Nabbed in Rs 27 Crore Hydroponic Marijuana Racket Busted by Delhi Police

JnJ seeks USFDA nod for Stelara in treatment of pediatric ulcerative colitis

Dr Reddy's Labs ropes in Srinivas Mallavarapu as Head, Global Portfolio and Head, Business Development, North America.

MSN Labs appoints Kalakuntla Srinivas Rao as Executive Vice President - Formulations Manufacturing Operations